Posts by: Marta Silva

Marta Silva

Marta Silva is a Molecular and Cellular Biologist, with research experience in the field of organic chemistry. After completing her bachelors degree, Marta earned a Masters in Biotechnology and she was a member of the Portuguese research institute of nano and microtechnology, INESC-MN.

January 4, 2016January 4, 2016

Allergens’ Risk to Respiratory Health Can Rise as Temperature Drop

News

Cooler months see people spending more time indoors and turning up the heating system. But heating units can stir up dust that has settled in carpets, air vents, and other areas throughout ... Read more

December 16, 2015December 16, 2015

Eiger BioPharmaceuticals Submits New Patent for Pulmonary Arterial Hypertension (PAH) Treatment

News, Pulmonary Hypertension

Eiger BioPharmaceuticals, Inc. recently announced the filing of a new patent for a novel PAH therapy. The company’s new “Treatment of Pulmonary Hypertension with Leukotriene Inhibitors” patent is designed to cover Bestatin™ (ubenimex), ... Read more

December 9, 2015December 9, 2015

Asthma, Hay Fever Double the Risk of Heart Disease in Children

Asthma, News

Children with allergic diseases such as asthma and hay fever have a higher rate of blood pressure and cholesterol, about twice that of other children, putting them at risk of heart disease ... Read more

December 7, 2015December 7, 2015

PFF Care Center Network Expands to 19 New Sites

Idiopathic Pulmonary Fibrosis, News

The Pulmonary Fibrosis Foundation (PFF) recently announced that 19 sites have been added to its Pulmonary Fibrosis Care Center Network, for a total of 40 sites in 26 states. The network a ... Read more

September 18, 2015November 5, 2015

PHA Symposium Aims to Promote Cross-functional Knowledge Exchange on PH Treatments

News, Pulmonary Hypertension

The Pulmonary Hypertension Association (PHA) is hosting the 2015 PH Professional Network (PHPN) Symposium, which began on Thursday, September 17 and will run until Saturday, September 19 at the Crystal Gateway ... Read more

September 17, 2015September 17, 2015

Preliminary Data From CAR-T Phase I Clinical Trial for NSCLC to be Presented by Cellular Biomedicine at 5th World Congress on Cancer Therapy

Lung Cancer, News

Cellular Biomedicine, a biotechnology company developing cell-based therapies to address degenerative diseases and immunotherapies for cancer, recently announced they will present new clinical findings at the 5th World Congress on Cancer Therapy, taking place on September 28, ... Read more

September 16, 2015November 5, 2015

Lung Transplant Rejection Reduced By New Filtering Technique

News, Pulmonary Hypertension

A new technique called lung filtering may offer hope for end-stage lung disease patients in need of a lung transplant. According to researchers from the University of Manchester, which is cooperating ... Read more

September 14, 2015November 5, 2015

Pulmatrix To Present Promising Inhaled CF Therapy PUR1900 at Cystic Fibrosis Conference

Cystic Fibrosis, News

Pulmatrix, a biotechnology company developing new inhaled therapies to address pulmonary diseases through the company’s own clinically validated technology iSPERSE, recently announced that their lead investigational therapy for CF will ... Read more

September 9, 2015November 5, 2015

Proteostasis Therapeutics To Use $37 Million in New Funding For Novel Cystic Fibrosis Therapy

Cystic Fibrosis, News

Yesterday, Proteostasis Therapeutics, Inc. (PTI) announced it had raised $37 million in new funding that will be used to develop its lead product candidate for the treatment of cystic fibrosis (CF) in human ... Read more

September 9, 2015November 5, 2015

Promedior Begins Phase 2 Clinical Trial for Novel IPF Treatment

Idiopathic Pulmonary Fibrosis, News

Promedior, a biotechnology company developing targeted therapeutics to treat a range of fibrotic diseases, announced the beginning of the second phase of their PRM-151 clinical trial in patients with Idiopathic Pulmonary Fibrosis ... Read more